{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:19:06Z","timestamp":1780633146660,"version":"3.54.1"},"reference-count":103,"publisher":"Informa UK Limited","issue":"10","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/14656566.2021.1888927","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T20:30:10Z","timestamp":1613766610000},"page":"1305-1318","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["An update on pharmacotherapeutic strategies for obesity"],"prefix":"10.1080","volume":"22","author":[{"given":"Beverly G.","family":"Tchang","sequence":"first","affiliation":[{"name":"Assistant Professor of Clinical Medicine, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Sirri","family":"Tarazi","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Fellow of Obesity Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Aras","sequence":"additional","affiliation":[{"name":"Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Fellow of Obesity Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana P.","family":"Shukla","sequence":"additional","affiliation":[{"name":"Assistant Professor of Research New York, Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"cit0001","first-page":"288","author":"Hales CM","year":"2017","journal-title":"Cent Dis Control Prevention"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.4158\/EP161688.PS"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.34"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00111"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59660"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2010.08.002"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437739.71477.ee"},{"key":"cit0009","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Developing Product for Weight Management. Division of Drug Information: Rockville, MD; 2007. p. 1\u201319."},{"key":"cit0010","volume-title":"Meridia: FDA drug safety communication: FDA recommends against the continued use of meridia (sibutramine)","author":"Food and Drug Administration","year":"2010"},{"key":"cit0011","unstructured":"Eisai. Belviq, Belviq XR (lorcaserin) by Eisai: Drug Safety Communication - FDA Requests Withdrawal of Weight-Loss Drug. 2020. Bethesda, MD: Food & Drug Administration (FDA)."},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1698291"},{"key":"cit0013","unstructured":"Xenical (orlistat) [package insert]. San Francisco, CA: Genentech USA, Inc. 1999."},{"key":"cit0014","author":"Wadden T","year":"2020","journal-title":"ObesityWeek"},{"key":"cit0015","volume-title":"A multiple-ascending-dose study to evaluate the efficacy, safety, and pharmacokinetics (PK) of MEDI0382 in overweight and obese participants with type 2 diabetes mellitus","author":"MedImmune LLC","year":"2019"},{"key":"cit0016","volume-title":"A study to evaluate the change in weight after 24 weeks treatment with LIK066 in obese or overweight adults","author":"Novartis Pharmaceuticals","year":"2017"},{"key":"cit0017","volume-title":"Effect of LIK066 on body weight in patients with elevated body mass index","author":"Novartis Pharmaceuticals","year":"2015"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11509-4"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.8.1288"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/69.6.1108"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.3.235"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.9.2.160"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2000.8"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.7.1123"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.6.1033"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01474.x"},{"key":"cit0028","unstructured":"Qsymia (phentermine and topiramate extended-release) [package insert]. Winchester, KY: VIVUS Inc. 2012."},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1993.tb01537.x"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.05.028"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2007.45"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20584"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.461"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30069-7"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12982"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2778"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2011.01280.x"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2204"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0930"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1558"},{"key":"cit0055","volume-title":"Naltrexone\/bupropion cardiovascular outcomes study. Bethesda, MD: National Library of Medicine","author":"Orexigen Therapeutics Inc","year":"2015"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13007"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2017.03.023"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13063"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00436-2"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2"},{"key":"cit0063","volume-title":"STEP 1: research study investigating how well semaglutide works in people suffering from overweight or obesity (STEP 1)","author":"Novo Nordisk A\/S","year":"2018"},{"key":"cit0064","volume-title":"Research study investigating how well semaglutide works in people with type 2 diabetes suffering from overweight or obesity","author":"Novo Nordisk A\/S","year":"2018"},{"key":"cit0065","volume-title":"Research study to look at how well semaglutide is at lowering weight when taken together with an intensive lifestyle program","author":"Novo Nordisk A\/S","year":"2018"},{"key":"cit0066","volume-title":"Research study investigating how well semaglutide works in people suffering from overweight or obesity","author":"Novo Nordisk A\/S","year":"2018"},{"key":"cit0067","volume-title":"Two-year research study investigating how well semaglutide works in people suffering from overweight or obesity","author":"Novo Nordisk A\/S","year":"2018"},{"key":"cit0068","volume-title":"STEP 6: research study investigating how well semaglutide works in people living with overweight or obesity","author":"Novo Nordisk A\/S","year":"2019"},{"key":"cit0069","volume-title":"Research study of how well semaglutide works in people living with overweight or obesity","author":"Novo Nordisk A\/S","year":"2020"},{"key":"cit0070","volume-title":"Research study to investigate how well semaglutide works compared to liraglutide in people living with overweight or obesity","author":"Novo Nordisk A\/S","year":"2019"},{"key":"cit0071","volume-title":"Semaglutide effects on heart disease and stroke in patients with overweight or obesity","author":"Novo Nordisk A\/S","year":"2018"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32260-8"},{"issue":"6","key":"cit0074","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias JP","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"cit0075","volume-title":"A study of tirzepatide (ly3298176) in participants with obesity or overweight","author":"Lilly E","year":"2019"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30726-8"},{"key":"cit0077","volume-title":"A study to evaluate the efficacy and safety of MEDI0382 in the treatment of overweight and obese subjects with type 2 diabetes","author":"AstraZeneca","year":"2017"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13654"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22764"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14006"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01307-13"},{"key":"cit0082","volume-title":"Safety, pharmacokinetics and efficacy of bimagrumab in overweight and obese patients with type 2 diabetes","author":"Novartis Pharmaceuticals","year":"2020"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0015-9"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512693"},{"key":"cit0085","unstructured":"FDA approves first treatment for weight management for people with certain rare genetic conditions [Internet]. https:\/\/www.fda.gov: U.S. Food and Drug Administration; 2020 [cited 2020 Sep 9]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-first-treatment-weight-management-people-certain-rare-genetic-conditions"},{"issue":"2","key":"cit0086","first-page":"39","volume":"13","author":"Wadden TA","year":"1989","journal-title":"Int J Obes"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105816"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21538"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17953"},{"key":"cit0090","unstructured":"Contrave (naltrexone HCl and bupropion HCl) [package insert]. San Diego, CA: Nalpropion Pharmaceuticals, Inc. 2014."},{"key":"cit0091","unstructured":"Saxenda (liraglutide 3.0mg) [package insert]. Plainsboro, NJ: Novo Nordisk; 2014."},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-017-0671-0"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1381\/096089202321144685"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1979-x"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1089\/bari.2018.0037"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1049-5"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5327"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12012"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1605"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2020.12.005"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.020"},{"key":"cit0102","author":"Acosta A","year":"2020","journal-title":"ObesityWeek"},{"key":"cit0103","volume-title":"A research study of how NNC0174\u20130833 taken with semaglutide works in people who are overweight or obese. 7\/26\/2018 ed","author":"Novo Nordisk A\/S","year":"2020"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.1888927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T11:06:43Z","timestamp":1625742403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.1888927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":103,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/14656566.2021.1888927"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.1888927","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}